Flibanserin Panel Review Will Pivot On Measurement Of Sexual Desire
This article was originally published in The Pink Sheet Daily
FDA's Reproductive Health Drugs Advisory Committee will weigh the best method for assessing the efficacy of Boehringer Ingelheim's Girosa for hypoactive sexual desire disorder in premenopausal women.
You may also be interested in...
Boehringer Ingelheim unable to show sufficient efficacy for Girosa in hypoactive sexual desire disorder in women.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.